Supplementary Table S1 from A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung Cancer
Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Fadlo R. Khuri(American University of Beirut Medical Center), Gabriel Sica(Emory University), Mourad Tighiouart(Cedars-Sinai Medical Center), Nabil F. Saba(Emory University), Zhengjia Chen(Hunan University of Traditional Chinese Medicine), R. Donald Harvey(Emory University), Michael R. Rossi(Sema4 (United States)), Seth Force(Emory Healthcare), Rabih Bechara(Piedmont Cancer Institute), Robert W. Fu(Emory University), William F. Auffermann(Emory University), Haian Fu(Emory University), Suresh S. Ramalingam(Emory University), Daniel Miller(New York State Department of Environmental Conservation), André Rogatko(Cedars-Sinai Medical Center), Sungjin Kim(Samueli Institute), Xingming Deng(Emory University), William E. Torres(Emory University), Allan Pickens(Emory University), Madhusmita Behera(National Institutes of Health), Anthony A. Gal(Emory University), Shi‐Yong Sun(Emory University)
Cited by 0
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k